Long‐Term Follow‐Up of Anti‐Infliximab Antibodies in Patients With Radiographic Axial Spondyloarthritis: A Marker of Drug Survival and Tapering.

MLA

Pimentel, Clarissa Q., et al. “Long‐Term Follow‐Up of Anti‐Infliximab Antibodies in Patients With Radiographic Axial Spondyloarthritis: A Marker of Drug Survival and Tapering.” Arthritis & Rheumatology, vol. 76, no. 10, Oct. 2024, pp. 1488–500. EBSCOhost, https://doi.org/10.1002/art.42923.

APA

Pimentel, C. Q., Medeiros, R. A. C., Shimabuco, A. Y., Sampaio, B. P. D., Moraes, J. C. B., Schainberg, C. G., Gonçalves, C. R., Leon, E. P., Kupa, L. D. V. K., Pasoto, S. G., Aikawa, N. E., Silva, C. A., Bonfa, E., & Saad, C. G. S. (2024). Long‐Term Follow‐Up of Anti‐Infliximab Antibodies in Patients With Radiographic Axial Spondyloarthritis: A Marker of Drug Survival and Tapering. Arthritis & Rheumatology, 76(10), 1488–1500. https://doi.org/10.1002/art.42923

Chicago

Pimentel, Clarissa Q., Ribeiro, Ana Cristina Medeiros, Andrea Y. Shimabuco, Barros, Percival D. Sampaio, Júlio César B. Moraes, Claudia G. Schainberg, Celio Roberto Gonçalves, et al. 2024. “Long‐Term Follow‐Up of Anti‐Infliximab Antibodies in Patients With Radiographic Axial Spondyloarthritis: A Marker of Drug Survival and Tapering.” Arthritis & Rheumatology 76 (10): 1488–1500. doi:10.1002/art.42923.